Healthcare giant Abbott (NYSE:ABT) is planning an immediate commercial launch, having won FDA clearance for its Tecnis Toric intraocular lens.
Abbott landed indication to market the Tecnis Toric lens to cataract patients with pre-existing corneal astigmatism, a condition in which the cornea of the lens in uneven, according to a company statement.
The Tecnis Toric lens, the latest in Abbott’s Tecnis line, is designed for implant into the eye in order to correct a loss of focus. The new product is "an additional lens option that provides proven visual outcomes to increase patient satisfaction," Abbott Medical Optics senior vice president Murthy Simhambhatla said in prepared remarks.
The medical products maker reported slower sales for its medical device operation but still logged sales growth during the 1st quarter. In its 1st earnings release since it split off its branded pharmaceuticals division as AbbVie (NYSE:ABBV), Abbott posted profits of $544 million, or 34¢ per share, on sales of $5.38 billion for the 3 months ended March 31.
